ArticleHepatology (Baltimore, Md.)2012
Interleukin-30: a novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury.
Article in Hepatology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- Prostatic fibroblast reprogramming by Interleukin-30 activates prostate cancer metastasis programs.Molecular biomedicine · 2026Article
- IL-30 protects against sepsis-induced myocardial dysfunction by inhibiting pro-inflammatory macrophage polarization and pyroptosis.iScience · 2023Article
- Screening differential circular RNA expression profiles reveals the regulatory role of circMARS in anti-tuberculosis drug-induced liver injury.Journal of cellular and molecular medicine · 2022Article
- Disrupting Interleukin 12 Improves Microvascular Endothelial Function in Type 2 Diabetes Through ER Stress CHOP and Oxidative Stress Mechanisms.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Interleukin-30 Suppresses Not Only CD4Biomedicines · 2021Article
- IL-30Experimental & molecular medicine · 2021Review
- Interleukin 27 Signaling in Rheumatoid Arthritis Patients: Good or Evil?Frontiers in immunology · 2021Review
- cDC1 IL-27p28 Production Predicts Vaccine-Elicited CD8Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Impact of Interleukin-27p28 on T and B Cell Responses during Toxoplasmosis.Infection and immunity · 2019Article
- IL-27, IL-30, and IL-35: A Cytokine Triumvirate in Cancer.Frontiers in oncology · 2019Review
- Cytokinome of adult-derived human liver stem/progenitor cells: immunological and inflammatory features.Hepatobiliary surgery and nutrition · 2018Article
- Interleukin (IL)-6 Inhibits IL-27- and IL-30-Mediated Inflammatory Responses in Human Monocytes.Frontiers in immunology · 2018Article
- Interleukin-27 signalling induces stem cell antigen-1 expression in T lymphocytes in vivo.Immunology · 2017Article
- IL27 controls skin tumorigenesis via accumulation of ETAR-positive CD11b cells in the pre-malignant skin.Oncotarget · 2016Article
- Dual Roles of IFN-γ and IL-4 in the Natural History of Murine Autoimmune Cholangitis: IL-30 and Implications for Precision Medicine.Scientific reports · 2016Article
- Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Systemic delivery of IL-27 by an adeno-associated viral vector inhibits T cell-mediated colitis and induces multiple inhibitory pathways in T cells.Journal of leukocyte biology · 2016Article
- Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cells.Journal of hepatology · 2016Article
- Mutant p53 in concert with an interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice.Hepatology (Baltimore, Md.) · 2016Article
- Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family.Frontiers in immunology · 2016Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledThe liver is the major metabolic organ and is subjected to constant attacks from chronic viral infection, uptake of therapeutic drugs, life behavior (alcoholic), and environmental contaminants, all of which result in chronic inflammation, fibrosis, and, ultimately, cancer. Therefore, there is an urgent need to discover effective therapeutic agents for the prevention and treatment of liver injury, the ideal drug being a naturally occurring biological inhibitor. Here we establish the role of IL30 as a potent antiinflammatory cytokine that can inhibit inflammation-induced liver injury. In contrast, interleukin (IL)27, which contains IL30 as a subunit, is not hepatoprotective. Interestingly, IL30 is induced by the proinflammatory signal such as IL12 through interferon-gamma (IFN-γ)/signal transducer and activator of transcription 1 signaling. In animal models, administration of IL30 by way of a gene therapy approach prevents and treats both IL12-, IFN-γ-, and concanavalin A-induced liver toxicity. Likewise, immunohistochemistry analysis of human tissue samples revealed that IL30 is highly expressed in hepatocytes, yet barely expressed in inflammation-induced tissue such as fibrous/connective tissue.
conclusionThese novel observations reveal a novel role of IL30 as a therapeutic cytokine that suppresses proinflammatory cytokine-associated liver toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.